Featured Research

from universities, journals, and other organizations

'Smat pill' reduces weight in overweight and obese subjects

Date:
June 23, 2014
Source:
Endocrine Society
Summary:
A new 'smart pill' called Gelesis100 leads to greater weight loss in overweight and obese individuals compared with those who receive an active comparator/placebo capsule, while all subjects have similar diet and exercise instructions, a new study finds.

A new "smart pill" called Gelesis100 safely leads to greater weight loss in overweight and obese individuals compared with those who receive an active comparator/placebo capsule, while all subjects have similar diet and exercise instructions, an international multicenter study finds. The three-month results of the First Loss Of Weight (FLOW) study were presented Sunday June 22, 2014 at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago.

Related Articles


Gelesis100 (formerly Attiva) is an orally administered capsulated device designed to cause weight loss by inducing satiety and reducing caloric intake, according to its manufacturer, Boston-headquartered Gelesis, which funded the FLOW study. In 128 nondiabetic subjects, weight loss was most pronounced in those who had impaired levels of fasting blood glucose (sugar), also known as prediabetes, said Hassan Heshmati, MD, chief medical officer for Gelesis and a study co-investigator.

"Given the excellent safety profile observed in the FLOW study, Gelesis100 has the potential to fulfill the unmet need for a safe and effective weight loss agent. This is particularly impactful for individuals with mildly elevated blood sugar (prediabetic subjects), for whom weight loss is particularly important because they are at increased risk for diabetes," Heshmati said.

This proof-of-concept study tested two doses of Gelesis100, a superabsorbent hydrogel, when taken twice a day with water before a meal. Forty-three subjects were randomly assigned to receive 2.25 grams (g) of Gelesis100 before lunch and dinner, another 42 subjects received 3.75 g of Gelesis100 and a third group of 43 subjects received a placebo capsule containing cellulose, a fiber which is used as a bulking agent. All subjects were instructed to eat 600 fewer calories a day. Neither the subjects nor the investigators knew which treatment they received during the 12 weeks of the study.

Among 125 subjects who weighed in at the start of the study and at least once after treatment, the average reductions in body weight by group at the end of treatment were as follows: 6.1 percent for 2.25 g of Gelesis100, 4.5 percent for 3.75 g of Gelesis100 and 4.1 percent for placebo. For subjects receiving the 2.25-g dose of Gelesis100, those with initial high fasting blood sugar (greater than the median level of 93 milligrams per deciliter, or mg/dL) had greater weight loss than did the others, losing 8.2 percent of their body weight on average, Heshmati reported.

The greatest weight loss reportedly occurred in prediabetic subjects whose starting fasting blood sugar level was 100 to 125.9 mg/dL. They lost an average of 10.9 percent of their body weight. Heshmati said he thinks the higher dose of Gelesis100 resulted in less weight loss because of lower tolerability leading to lower compliance with the study requirements. The most common side effects reported were bloating, flatulence, abdominal pain and diarrhea, which he said occurred less often with the smaller dose and were tolerable at that dose. No apparent serious problems occurred in either Gelesis100 group.

Gelesis100 capsules contain thousands of tiny hydrogel particles that expand in the stomach and mix with digested foods, said Gelesis' founder and chief executive officer, Yishai Zohar. He said this increases the volume and elasticity of the stomach and small intestine contents, inducing satiety and reducing caloric intake. The particles are composed of two components which are used as food ingredients, but when cross-linked together form a unique structure that increases in volume. Gelesis100 does not create one big mass, rather thousands of small individual gel beads which have exactly the same elasticity (rigidity) as digested foods, but without any calories.

The first in a new class of weight management and obesity therapies, Gelesis100 will be regulated as a medical device if approved by the Food and Drug Administration, Zohar said.


Story Source:

The above story is based on materials provided by Endocrine Society. Note: Materials may be edited for content and length.


Cite This Page:

Endocrine Society. "'Smat pill' reduces weight in overweight and obese subjects." ScienceDaily. ScienceDaily, 23 June 2014. <www.sciencedaily.com/releases/2014/06/140623141859.htm>.
Endocrine Society. (2014, June 23). 'Smat pill' reduces weight in overweight and obese subjects. ScienceDaily. Retrieved March 3, 2015 from www.sciencedaily.com/releases/2014/06/140623141859.htm
Endocrine Society. "'Smat pill' reduces weight in overweight and obese subjects." ScienceDaily. www.sciencedaily.com/releases/2014/06/140623141859.htm (accessed March 3, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Tuesday, March 3, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Treadmill Test Can Predict Chance Of Death Within A Decade

Treadmill Test Can Predict Chance Of Death Within A Decade

Newsy (Mar. 2, 2015) Johns Hopkins researchers analyzed 58,000 heart stress tests to come up with a formula that predicts a person&apos;s chances of dying in the next decade. Video provided by Newsy
Powered by NewsLook.com
Going Gluten-Free Could Get You A Tax Break

Going Gluten-Free Could Get You A Tax Break

Newsy (Mar. 2, 2015) If a doctor advises you to remove gluten from your diet, you could get a tax deduction on the amount you spend on gluten-free foods. Video provided by Newsy
Powered by NewsLook.com
GlaxoSmithKline and Novartis Try Swapping Success

GlaxoSmithKline and Novartis Try Swapping Success

Reuters - Business Video Online (Mar. 2, 2015) GlaxoSmithKline and Novartis have completed a series of asset swaps worth more than $20 billion. As Grace Pascoe reports they say the deal will reshape both drugmakers. Video provided by Reuters
Powered by NewsLook.com
How Can West Africa Rebuild After Ebola?

How Can West Africa Rebuild After Ebola?

Reuters - Business Video Online (Mar. 2, 2015) How best to rebuild the three West African countries struggling with Ebola will be discussed in Brussels this week. As Hayley Platt reports Sierra Leone has the toughest job ahead - its once thriving economy has been ravaged by the disease. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins